Nightingale Health to publish Financial Statements Release for financial year July 2023 – June 2024 on 20 September 2024
Nightingale Health Plc
Press release
5 September 2024 at 2:30 p.m. (EEST)
Nightingale Health Plc (“Nightingale Health”), a pioneer in disease risk detection and preventative health, will publish its financial statements release for the financial year July 2023 – June 2024 on Friday 20 September 2024 at around 9 a.m. EEST. Materials will be made available soon after publication at https://ir.nightingalehealth.com/.
Nightingale will arrange a live webcast for investors and media in English on 20 September 2024 at 2 p.m. EEST. You can watch the webcast online at https://nightingalehealth.videosync.fi/2023-2024-results.
Presentation is held by CEO Teemu Suna and CFO Tuukka Paavola. A recording of the event will be available later the same day at https://ir.nightingalehealth.com/.
For further information, please contact:
Teemu Suna, CEO
About Nightingale Health
Nightingale Health’s mission is to build sustainable healthcare and reduce health inequalities. Nightingale Health has developed the world’s most advanced health check that provides risk detection for multiple chronic diseases from a single blood sample. Nightingale’s Health Check can be scaled to entire populations at a low cost, and it can replace many of the current clinical risk assessments. Detecting disease risks on a population level allows for the effective targeting and tracking of health interventions, and better prevention of the onset of chronic diseases. With every sample we help to create a healthier world.
Nightingale Health operates globally with a parent company in Finland and seven subsidiaries in countries such as Japan, the United States, Singapore, and the United Kingdom. Nightingale Health has customers in more than 34 countries in the healthcare and medical research sectors. The company’s technology is being used in many of the world’s leading health initiatives, such as the UK Biobank, and over 600 peer-reviewed publications validate the technology. The company’s Series B shares are listed on the First North Growth Market Finland marketplace. Read more: https://nightingalehealth.com
Tags:
